Copner Biotech
Develops proprietary GRAPE® software and bioprinting systems for high-precision 3D cell culture scaffolds and tissue engineering, enabling additive manufacturing of accurate, repeatable biological models.
- CEO / Founder
- Jordan Copner
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $715K
- Latest Round
- Grant
- Key Investors
- Innovate UK; Welsh Government; BBSRC
Technology & Products
Key Products
GRAPE S1 4D Extrusion Bioprinter; 3D Inkjet Bioprinter (in development); 3D PETG Cell Culture Scaffolds; GRAPE® modeling software; Custom scaffold design services
Technological Advantage
Patented method for 3D printing low-viscosity bio-inks (GB2609532) and additive manufacturing process (GB2206780.5), achieving <100μm resolution for fine tissue structures, protected by 2+ UK patents with additional filings pending.
Differentiation
Value Proposition
Reduces 3D cell culture scaffold production time by 70% (from weeks to days) with batch-to-batch consistency >99%, enabling researchers to model physiological conditions more accurately for applications like cancer research and organoid development.
How They Differentiate
Offers 3x higher resolution (<100μm vs. industry standard >200μm) for bioprinted tissues and proprietary software enabling concentric scaffold designs, unlike competitors relying on standard STL files and g-code.
Market & Competition
Target Customers
Biotechnology researchers, academic labs, pharmaceutical companies, and tissue engineering firms
Industry Verticals
Biotechnology; Pharmaceuticals; Academic Research; Medical Devices
Competitors
Thermo Fisher Scientific (3D cell culture systems); Merck (3D cell culture technologies); Lonza Group (cell culture solutions); Corning Incorporated (3D cell culture products)
Growth & Milestones
Growth Metrics
Secured £400,000 ($483,000) Innovate UK funding in 2022; launched Early Adopters Program for bioprinter prototypes; completed SMART Cymru-funded project with Jellagen in 2022.
Major Milestones
Founded in 2020; Awarded Innovate UK funding (£400,000) in 2022; Completed collaborative project with Jellagen Ltd in 2022; Launched Early Adopters Program for bioprinters; Granted multiple UK patents (GB2609532, GB2206780.5)
Notable Customers
Early Adopters Program participants in the UK (specific names undisclosed); Research labs using PETG scaffolds for organoid culture